Successful immunomodulation in kidney transplant recipients with cytokine release syndrome after coronavirus disease
© 2022 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association..
Introduction: Patients with coronavirus disease, especially solid organ transplant recipients, are more susceptible to developing cytokine release syndrome than those with other viral infections. However, currently, treatment methods for such patients have not been established. Here, we describe two cases of successful immunomodulation in Japanese kidney transplant recipients with cytokine release syndrome following coronavirus disease.
Case presentation: Two patients who had been receiving long-term immunosuppressant therapy developed coronavirus disease-associated pneumonia caused by cytokine release syndrome, following immunosuppressant dosage reduction. However, they recovered immediately after administration of tocilizumab with or without dexamethasone.
Conclusion: The immunosuppressant dosage should be reduced to restore host immunity; however, immunomodulation should be considered in cases of suspected cytokine release syndrome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
IJU case reports - 5(2022), 5 vom: 15. Sept., Seite 373-377 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Takamoto, Daiji [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID‐19 |
|---|
| Anmerkungen: |
Date Revised 13.10.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/iju5.12492 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344614921 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344614921 | ||
| 003 | DE-627 | ||
| 005 | 20231226023200.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/iju5.12492 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1148.xml |
| 035 | |a (DE-627)NLM344614921 | ||
| 035 | |a (NLM)35942072 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Takamoto, Daiji |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Successful immunomodulation in kidney transplant recipients with cytokine release syndrome after coronavirus disease |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.10.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association. | ||
| 520 | |a Introduction: Patients with coronavirus disease, especially solid organ transplant recipients, are more susceptible to developing cytokine release syndrome than those with other viral infections. However, currently, treatment methods for such patients have not been established. Here, we describe two cases of successful immunomodulation in Japanese kidney transplant recipients with cytokine release syndrome following coronavirus disease | ||
| 520 | |a Case presentation: Two patients who had been receiving long-term immunosuppressant therapy developed coronavirus disease-associated pneumonia caused by cytokine release syndrome, following immunosuppressant dosage reduction. However, they recovered immediately after administration of tocilizumab with or without dexamethasone | ||
| 520 | |a Conclusion: The immunosuppressant dosage should be reduced to restore host immunity; however, immunomodulation should be considered in cases of suspected cytokine release syndrome | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a COVID‐19 | |
| 650 | 4 | |a cytokine release syndrome | |
| 650 | 4 | |a dexamethasone | |
| 650 | 4 | |a kidney transplant recipient | |
| 650 | 4 | |a tocilizumab | |
| 700 | 1 | |a Sasaki, Hajime |e verfasserin |4 aut | |
| 700 | 1 | |a Kataoka, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kodama, Fumihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Higuchi, Haruka |e verfasserin |4 aut | |
| 700 | 1 | |a Hirano, Tetsuo |e verfasserin |4 aut | |
| 700 | 1 | |a Takada, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Harada, Shigeru |e verfasserin |4 aut | |
| 700 | 1 | |a Harada, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Hiroshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t IJU case reports |d 2018 |g 5(2022), 5 vom: 15. Sept., Seite 373-377 |w (DE-627)NLM313187118 |x 2577-171X |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2022 |g number:5 |g day:15 |g month:09 |g pages:373-377 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/iju5.12492 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2022 |e 5 |b 15 |c 09 |h 373-377 | ||